294 related articles for article (PubMed ID: 34697216)
1. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.
Xu Y; Gao Z; Hu R; Wang Y; Wang Y; Su Z; Zhang X; Yang J; Mei M; Ren Y; Li M; Zhou X
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34697216
[TBL] [Abstract][Full Text] [Related]
2. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
4. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
Front Immunol; 2019; 10():1644. PubMed ID: 31379843
[No Abstract] [Full Text] [Related]
5. Tumor-Specific Antibody, Cetuximab, Enhances the
Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
Front Immunol; 2020; 11():591139. PubMed ID: 33281820
[TBL] [Abstract][Full Text] [Related]
6. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response.
Korpela SP; Hinz TK; Oweida A; Kim J; Calhoun J; Ferris R; Nemenoff RA; Karam SD; Clambey ET; Heasley LE
J Transl Med; 2021 Jan; 19(1):43. PubMed ID: 33485341
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Mediates Dysfunction in Activated PD-1
Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
[TBL] [Abstract][Full Text] [Related]
9. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
[TBL] [Abstract][Full Text] [Related]
10. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
Baysal H; De Pauw I; Zaryouh H; De Waele J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; Jacobs J; Wouters A
Br J Cancer; 2020 Sep; 123(5):752-761. PubMed ID: 32541873
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.
Okuyama K; Naruse T; Yanamoto S
J Exp Clin Cancer Res; 2023 May; 42(1):114. PubMed ID: 37143088
[TBL] [Abstract][Full Text] [Related]
13. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
14. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
[No Abstract] [Full Text] [Related]
15. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma.
Ma H; Chang H; Yang W; Lu Y; Hu J; Jin S
Mol Cancer; 2020 Jan; 19(1):4. PubMed ID: 31907020
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
[TBL] [Abstract][Full Text] [Related]
17. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
18. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
19. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]